The role of the gut microbiota in energy metabolism and metabolic disease - PubMed (original) (raw)
Review
The role of the gut microbiota in energy metabolism and metabolic disease
Patrice D Cani et al. Curr Pharm Des. 2009.
Abstract
Obesity is now classically characterized by a cluster of several metabolic disorders, and by a low grade inflammation. The evidence that the gut microbiota composition can be different between healthy and or obese and type 2 diabetic patients has led to the study of this environmental factor as a key link between the pathophysiology of metabolic diseases and the gut microbiota. Several mechanisms are proposed linking events occurring in the colon and the regulation of energy metabolism, such as i.e. the energy harvest from the diet, the synthesis of gut peptides involved in energy homeostasis (GLP-1, PYY...), and the regulation of fat storage. Moreover, the development of obesity and metabolic disorders following a high-fat diet may be associated to the innate immune system. Indeed, high-fat diet feeding triggers the development of obesity, inflammation, insulin resistance, type 2 diabetes and atherosclerosis by mechanisms dependent of the LPS and/or the fatty acids activation of the CD14/TLR4 receptor complex. Importantly, fat feeding is also associated with the development of metabolic endotoxemia in human subjects and participates in the low-grade inflammation, a mechanism associated with the development of atherogenic markers. Finally, data obtained in experimental models and human subjects are in favour of the fact that changing the gut microbiota (with prebiotics and/or probiotics) may participate in the control of the development of metabolic diseases associated with obesity. Thus, it would be useful to find specific strategies for modifying gut microbiota to impact on the occurrence of metabolic diseases.
Similar articles
- Pathophysiological role of host microbiota in the development of obesity.
Kobyliak N, Virchenko O, Falalyeyeva T. Kobyliak N, et al. Nutr J. 2016 Apr 23;15:43. doi: 10.1186/s12937-016-0166-9. Nutr J. 2016. PMID: 27105827 Free PMC article. Review. - Probiotics, prebiotics, energy balance, and obesity: mechanistic insights and therapeutic implications.
Molinaro F, Paschetta E, Cassader M, Gambino R, Musso G. Molinaro F, et al. Gastroenterol Clin North Am. 2012 Dec;41(4):843-54. doi: 10.1016/j.gtc.2012.08.009. Gastroenterol Clin North Am. 2012. PMID: 23101690 Review. - Gut microbiota, intestinal permeability, obesity-induced inflammation, and liver injury.
Frazier TH, DiBaise JK, McClain CJ. Frazier TH, et al. JPEN J Parenter Enteral Nutr. 2011 Sep;35(5 Suppl):14S-20S. doi: 10.1177/0148607111413772. Epub 2011 Aug 1. JPEN J Parenter Enteral Nutr. 2011. PMID: 21807932 Review. - The gut microbiota, obesity and insulin resistance.
Shen J, Obin MS, Zhao L. Shen J, et al. Mol Aspects Med. 2013 Feb;34(1):39-58. doi: 10.1016/j.mam.2012.11.001. Epub 2012 Nov 16. Mol Aspects Med. 2013. PMID: 23159341 Review. - Gut microbiota and the development of obesity.
Boroni Moreira AP, Fiche Salles Teixeira T, do C Gouveia Peluzio M, de Cássia Gonçalves Alfenas R. Boroni Moreira AP, et al. Nutr Hosp. 2012 Sep-Oct;27(5):1408-14. doi: 10.3305/nh.2012.27.5.5887. Nutr Hosp. 2012. PMID: 23478685 Review.
Cited by
- Lactobacillus reuteri TSR332 and Lactobacillus fermentum TSF331 stabilize serum uric acid levels and prevent hyperuricemia in rats.
Kuo YW, Hsieh SH, Chen JF, Liu CR, Chen CW, Huang YF, Ho HH. Kuo YW, et al. PeerJ. 2021 May 3;9:e11209. doi: 10.7717/peerj.11209. eCollection 2021. PeerJ. 2021. PMID: 33986988 Free PMC article. - Restoring specific lactobacilli levels decreases inflammation and muscle atrophy markers in an acute leukemia mouse model.
Bindels LB, Beck R, Schakman O, Martin JC, De Backer F, Sohet FM, Dewulf EM, Pachikian BD, Neyrinck AM, Thissen JP, Verrax J, Calderon PB, Pot B, Grangette C, Cani PD, Scott KP, Delzenne NM. Bindels LB, et al. PLoS One. 2012;7(6):e37971. doi: 10.1371/journal.pone.0037971. Epub 2012 Jun 27. PLoS One. 2012. PMID: 22761662 Free PMC article. - Fighting fire with fire: is it time to use probiotics to manage pathogenic bacterial diseases?
Heineman J, Bubenik S, McClave S, Martindale R. Heineman J, et al. Curr Gastroenterol Rep. 2012 Aug;14(4):343-8. doi: 10.1007/s11894-012-0274-4. Curr Gastroenterol Rep. 2012. PMID: 22763792 Review. - Chemopreventive Metabolites Are Correlated with a Change in Intestinal Microbiota Measured in A-T Mice and Decreased Carcinogenesis.
Cheema AK, Maier I, Dowdy T, Wang Y, Singh R, Ruegger PM, Borneman J, Fornace AJ Jr, Schiestl RH. Cheema AK, et al. PLoS One. 2016 Apr 13;11(4):e0151190. doi: 10.1371/journal.pone.0151190. eCollection 2016. PLoS One. 2016. PMID: 27073845 Free PMC article. - Starch-protein interaction effects on lipid metabolism and gut microbes in host.
Wang K, Zhou M, Gong X, Zhou Y, Chen J, Ma J, Zhang P. Wang K, et al. Front Nutr. 2022 Nov 16;9:1018026. doi: 10.3389/fnut.2022.1018026. eCollection 2022. Front Nutr. 2022. PMID: 36466418 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials